Skip to main content
Erschienen in: World Journal of Urology 1/2018

07.11.2017 | Original Article

Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques

verfasst von: J. W. Yaxley, J. Dagher, B. Delahunt, L. Egevad, J. Srigley, H. Samaratunga

Erschienen in: World Journal of Urology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Performing an extended pelvic lymph node dissection (PLND) on all men with intermediate- and high-risk prostate cancer at the time of a radical prostatectomy (RP) remains controversial. The majority of patients PLND histology is benign, and the long-term cancer-free progression in men with positive lymph node metastasis is low. The objective is to investigate the probability of long-term biochemical freedom from recurrent disease (bNED) in men with lymph node metastasis identified at the time of radical prostatectomy (RP).

Subjects and methods

A retrospective review of the pathology of 1184 pelvic lymph node dissections performed at the time of a radical prostatectomy by multiple surgeons referred to a single uro-pathology laboratory between 2008 and 2014 identified 61 men with node-positive prostate cancer. Of the men with positive nodes, 24 had a standard PLND and 37 an extended PLND (ePLND). bNED was defined as a post-operative serum PSA < 0.2 ng/ml.

Results

The median follow-up is 4 years (2–8). The median lymph node count was 7 (range 2–16) for PLND and 22 (range 6–46) for the ePLND. A single lymph node metastasis was identified in 56% of the 61 men. Only 10% of men with a positive lymph node metastasis remained free of biochemical recurrence of disease, and only 5% had undetectable serum PSA. There was no difference in bNED outcome between a PLND and ePLND. The number of men needed to be treated with a PLND at the time of RP (NNT) to result in an undetectable post-operative PSA at a median follow-up of 4 years is 395.

Conclusions

In men with lymph node metastasis, the probability of long-term bNED is low and the NNT for cure is high. With emerging improved radiological imaging techniques increasing the detection of lymph node metastasis outside the extended lymph node dissection templates, more scientific investigation is required to evaluate which men will benefit from a PLND and which men can avoid an unnecessary PLND procedure.
Literatur
1.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumerbatch M, Santis M, European Association of Urology Guidelines-EAU-ESTRO-SIOS et al (2017) Guidelines on prostate cancer part 1: screening, diagnosis and local treatment with curative intent. Eur Urol 71(4):618–629CrossRefPubMed Mottet N, Bellmunt J, Bolla M, Briers E, Cumerbatch M, Santis M, European Association of Urology Guidelines-EAU-ESTRO-SIOS et al (2017) Guidelines on prostate cancer part 1: screening, diagnosis and local treatment with curative intent. Eur Urol 71(4):618–629CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Seigel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249CrossRefPubMed Jemal A, Seigel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249CrossRefPubMed
3.
Zurück zum Zitat Cagiannos I, Karakiewicz P, Eastham JA et al (2003) A pre-operative nomogram identifying disease risk of positive pelvic nodes in patients with prostate cancer. J Urol 170(5):1798–1803CrossRefPubMed Cagiannos I, Karakiewicz P, Eastham JA et al (2003) A pre-operative nomogram identifying disease risk of positive pelvic nodes in patients with prostate cancer. J Urol 170(5):1798–1803CrossRefPubMed
4.
Zurück zum Zitat Yaxley JW, Coughlin GD, Chambers SK et al (2016) Robot-assisted laparoscopic prostatectomy versus open radical prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 388(10049):1057–1066CrossRefPubMed Yaxley JW, Coughlin GD, Chambers SK et al (2016) Robot-assisted laparoscopic prostatectomy versus open radical prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 388(10049):1057–1066CrossRefPubMed
5.
Zurück zum Zitat Briganti A, Chun FK-H, Salonia A et al (2006) Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate. Cancer 50:1006–1013 Briganti A, Chun FK-H, Salonia A et al (2006) Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate. Cancer 50:1006–1013
8.
Zurück zum Zitat Perry-Keene J, Ferguson P, Samaratunga H et al (2014) Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases yield and detection of micrometastasis. Histopathology 64:399–404CrossRefPubMed Perry-Keene J, Ferguson P, Samaratunga H et al (2014) Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases yield and detection of micrometastasis. Histopathology 64:399–404CrossRefPubMed
9.
Zurück zum Zitat Tuoijer KA, Mazzalo CR, Sjoberg DD, Scardino PT, Eastham JA (2014) Long term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen deprivation therapy. Eur Urol 65:20–25CrossRef Tuoijer KA, Mazzalo CR, Sjoberg DD, Scardino PT, Eastham JA (2014) Long term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen deprivation therapy. Eur Urol 65:20–25CrossRef
10.
Zurück zum Zitat Seiler R, Studer U, Tschan K, Bader P, Burkhard FC (2014) Removal of limited nodal disease in patients undergoing radical prostatectomy: long term results confirm a chance for cure. J Urol 191:1280–1285CrossRefPubMed Seiler R, Studer U, Tschan K, Bader P, Burkhard FC (2014) Removal of limited nodal disease in patients undergoing radical prostatectomy: long term results confirm a chance for cure. J Urol 191:1280–1285CrossRefPubMed
11.
Zurück zum Zitat Pierorazio PM, Gorin MA, Ross AE et al (2013) Pathological and oncological outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins 30 year experience. Prostate 73:1673–1680PubMed Pierorazio PM, Gorin MA, Ross AE et al (2013) Pathological and oncological outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins 30 year experience. Prostate 73:1673–1680PubMed
12.
Zurück zum Zitat Afhar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with (68) Ga—labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20CrossRef Afhar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with (68) Ga—labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20CrossRef
13.
Zurück zum Zitat Perera M, Papa N, Christidid D et al (2016) Sensitivity, specificity and predictors of positive 68Ga-prostate specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed Perera M, Papa N, Christidid D et al (2016) Sensitivity, specificity and predictors of positive 68Ga-prostate specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed
14.
Zurück zum Zitat Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1436–1443CrossRefPubMed Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1436–1443CrossRefPubMed
15.
Zurück zum Zitat Meredith G, Wong D, Yaxley J et al (2016) The use of 68Ga-PSMA PET/CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 118:49–55CrossRefPubMed Meredith G, Wong D, Yaxley J et al (2016) The use of 68Ga-PSMA PET/CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 118:49–55CrossRefPubMed
16.
Zurück zum Zitat Birkháuser FD, Studer UE, Froehlich JM et al (2013) Combined supraparamagnetic particles of iron oxide enhanced and diffusion weighted MRI facilitates detection of metastasis in normal sized lymph nodes in bladder and prostate cancer. Eur Urol 64:953–960CrossRefPubMed Birkháuser FD, Studer UE, Froehlich JM et al (2013) Combined supraparamagnetic particles of iron oxide enhanced and diffusion weighted MRI facilitates detection of metastasis in normal sized lymph nodes in bladder and prostate cancer. Eur Urol 64:953–960CrossRefPubMed
17.
Zurück zum Zitat Mattei A, Fuechsel F, Dhar N et al (2008) The template of primary lymphatic landing sites of the prostate should be revisited: results of multimodality mapping study. Eur Urol 53:118–125CrossRefPubMed Mattei A, Fuechsel F, Dhar N et al (2008) The template of primary lymphatic landing sites of the prostate should be revisited: results of multimodality mapping study. Eur Urol 53:118–125CrossRefPubMed
18.
Zurück zum Zitat Alemozaffar M, Sandra M, Yecles D et al (2015) Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the health professionals follow up study. Eur Urol 67(3):432–438CrossRefPubMed Alemozaffar M, Sandra M, Yecles D et al (2015) Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the health professionals follow up study. Eur Urol 67(3):432–438CrossRefPubMed
19.
Zurück zum Zitat Osmonov DV, Askenov AV, Jilig CA et al (2016) Salvage lymphadenectomy in patients with prostate cancer recurrence. Urol A 55:208–217CrossRef Osmonov DV, Askenov AV, Jilig CA et al (2016) Salvage lymphadenectomy in patients with prostate cancer recurrence. Urol A 55:208–217CrossRef
20.
Zurück zum Zitat Suarti N, Gandaglia G, Gallina A et al (2015) Long term outcomes of salvage pelvic lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67:299–309CrossRef Suarti N, Gandaglia G, Gallina A et al (2015) Long term outcomes of salvage pelvic lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67:299–309CrossRef
21.
Zurück zum Zitat Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L et al (2017) Robot assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJUI. https://doi.org/10.1111/bju13919 Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L et al (2017) Robot assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJUI. https://​doi.​org/​10.​1111/​bju13919
22.
Zurück zum Zitat van Leeuwen PJ, Emmett L, Ho B et al (2017) Prospective evaluation of Gallium-prostate specific membrane antigen positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed van Leeuwen PJ, Emmett L, Ho B et al (2017) Prospective evaluation of Gallium-prostate specific membrane antigen positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed
23.
Zurück zum Zitat Budaus L, Leyh-Bannurah S, Salomon G et al (2016) Initial experience of (68)Ga-PSMA PET/CT imaging in high risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393–396CrossRefPubMed Budaus L, Leyh-Bannurah S, Salomon G et al (2016) Initial experience of (68)Ga-PSMA PET/CT imaging in high risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393–396CrossRefPubMed
26.
Zurück zum Zitat Gakis G, Boorjiah SA, Briganti A et al (2014) The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66(2):191–199CrossRefPubMed Gakis G, Boorjiah SA, Briganti A et al (2014) The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66(2):191–199CrossRefPubMed
Metadaten
Titel
Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques
verfasst von
J. W. Yaxley
J. Dagher
B. Delahunt
L. Egevad
J. Srigley
H. Samaratunga
Publikationsdatum
07.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2119-0

Weitere Artikel der Ausgabe 1/2018

World Journal of Urology 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.